awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37154344-866A4094-B0EC-4C8E-86BD-46581934087B
Q37154344-866A4094-B0EC-4C8E-86BD-46581934087B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37154344-866A4094-B0EC-4C8E-86BD-46581934087B
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
P2860
Q37154344-866A4094-B0EC-4C8E-86BD-46581934087B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37154344-866A4094-B0EC-4C8E-86BD-46581934087B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4b851b0fcb2e020533ccb14ee0f6f1457cd951c2
P2860
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.